title: [Blood coagulation changes and neoplastic pathology].
abstract: Cancer patients show an increased susceptibility to develop thromboembolic diseases, suggesting that disorders of coagulation are very common in this pathology. Tumor cells possess the capacity to interact with the hemostatic system, activating the coagulation cascade and stimulating the prothrombotic properties of other blood cell components; the same events while inducing a hypercoagulable state, also contribute to the processes of tumor growth, neoangiogenesis and metastatic formation. Multiple risk factors associated with malignant disease contribute to the hypercoagulability state: stasis induced by prolonged bed rest, vascular invasion by the tumor and iatrogenic complications including the use of central vein catheters and chemotherapy. Several tests have been developed to assess the hypercoagulable state, however their clinical significance still needs to be defined, especially in terms of their predictive value for thrombosis. Clinical manifestations vary from localized deep venous thrombosis (DVT) or pulmonary embolism, more generally associated with solid tumors, to disseminated intravascular coagulation, frequent in hematologic malignancies and metastatic cancer. Diagnosis of idiopathic DVT, in the absence of other risk factors, could indicate the presence of occult cancer, but the usefulness of an extensive work-up to detect malignancy in terms of cost to benefit ratio still has to be demonstrated. Patients with cancer and thromboembolism must be treated with anticoagulant therapy; a large number of studies have shown that either low molecular weight heparins or standard unfractionated heparin for the treatment of acute deep vein thrombosis in hospitalized patients are equally safe and effective; however, the first treatment has been reported to be associated with a lower mortality. After an episode of thrombosis the patients should be protected by a long term course of oral anticoagulation, remaining high the risk of recurrence for as long as the cancer is active.
authors.affiliation: Dipartimento di Medicina Interna e Sanità Pubblica, Università, L'Aquila.
authors.forename: M P
authors.initials: MP
authors.lastname: Corsi
authors.forename: M
authors.initials: M
authors.lastname: De Martinis
authors.forename: G
authors.initials: G
authors.lastname: Di Leonardo
authors.forename: M F
authors.initials: MF
authors.lastname: Loreto
authors.forename: M
authors.initials: M
authors.lastname: Modesti
authors.forename: D
authors.initials: D
authors.lastname: Quaglino
mesh_terms: D001777:Blood Coagulation / Q000502:physiology; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications* / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D013927:Thrombosis / Q000150:complications / Q000209:etiology / Q000628:therapy